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The three-dimensional structure of caspase-8: an initiator
enzyme in apoptosis
Helen Blanchard1, Lalitha Kodandapani2, Peer RE Mittl1,3, Stefania Di Marco3,4,
Joseph F Krebs2, Joe C Wu2, Kevin J Tomaselli2 and Markus G Grütter1,3*
Background: In the initial stages of Fas-mediated apoptosis the cysteine
protease caspase-8 is recruited to the cell receptor as a zymogen (procaspase-8)
and is incorporated into the death-signalling complex. Procaspase-8 is
subsequently activated leading to a cascade of proteolytic events, one of them
being the activation of caspase-3, and ultimately resulting in cell destruction.
Variations in the substrate specificity of different caspases have been reported.
Results: We report here the crystal structure of a complex of the activated
human caspase-8 (proteolytic domain) with the irreversible peptidic inhibitor
Z-Glu-Val-Asp-dichloromethylketone at 2.8 Å resolution. This is the first
structure of a representative of the long prodomain initiator caspases and of the
group III substrate specificity class. The overall protein architecture resembles
the caspase-1 and caspase-3 folds, but shows distinct structural differences in
regions forming the active site. In particular, differences observed in subsites
S3, S4 and the loops involved in inhibitor interactions explain the preference of
caspase-8 for substrates with the sequence (Leu/Val)-Glu-X-Asp.
Conclusions: The structural differences could be correlated with the observed
substrate specificities of caspase-1, caspase-3 and caspase-8, as determined
from kinetic experiments. This information will help us to understand the role of the
various caspases in the propagation of the apoptotic signal. The information
gained from this investigation should be useful for the design of specific inhibitors.
Introduction
Programmed cell death (apoptosis) is an essential mecha-
nism to maintain the integrity and homeostasis of multicel-
lular organisms [1,2]. Excessive apoptosis leads to disorders
including neurodegenerative diseases, whereas conditions
such as cancer result from insufficient apoptosis (reviewed
in [3]). The apoptotic process involves an intricate cascade
of events that appear to follow two major pathways: one
relies on a cell surface stimulus, that of Fas-mediated or
granzyme B mediated apoptosis; the other occurs as a con-
sequence of cellular stress and is mediated by cytochrome
c. Although the exact details of these controlled cell-death
pathways have still to be fully determined, it has been
established by biochemical and genetic approaches that the
cysteine proteases caspases (cysteine aspartate proteases)
have an essential role at various stages of the apoptotic
process (reviewed in [4]). Procaspase-8 is an enzymatic
component of cell-death pathways that incorporate the
tumour necrosis factor receptor family members Fas 
(Apo-1/CD95), the 55 kDa tumour necrosis factor receptor,
and death receptor-3 [5–7]. Activation of the cell suicide
machinery can occur via the binding of the Fas ligand to
Fas receptors on the surface of the target cells. This triggers
Fas-associated death domain protein (FADD) adapter mol-
ecules to associate with the receptors and procaspase-8 is
subsequently recruited, forming part of the death inducing
signalling complex (DISC) [7,8]. The long prodomain
region of procaspase-8 which has amino acid sequence
homology to the FADD death effector domain (DED),
associates with the DED of FADD. There is strong evi-
dence that the association of at least two proenzyme chains
is required for autoproteolytic activation of the zymogen to
give the four-chain active enzyme [8,9]. The association of
procaspase-8 with FADD, coupled with recent experi-
ments showing that caspase-8 directly processes the execu-
tioner procaspase-3 [10], substantiates the important
biological function of caspase-8 in initiating the apoptotic
cascade. Caspase-8 also has a possible role in a cross-talk
mechanism between the two major apoptotic pathways via
the cleavage of the protein BID which is a proapoptotic
member of the bcl-2 family [11] (reviewed in [4]). 
On the basis of phylogenetic analysis the caspases have
been classified into two subfamilies, ICE and CED-3, for
which the prototypes are interleukin-1β converting
enzyme (caspase-1) and the Caenorhabditis elegans protein
CED-3. All caspases show a high degree of specificity
with an absolute requirement for cleavage after aspartic
acid, and a recognition sequence of at least four amino
acids N-terminal to the cleavage site. This characteristic
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specificity is important to the apoptotic process as it
involves cleavage of a particular group of proteins in an
ordered manner rather than indiscriminate proteolysis
[12]. A combinatorial approach has been used to deter-
mine the tetrapeptide substrate specificity of a number of
human caspases [13]. They have been classified into three
distinct specificity groups: group I (caspases-1, -4 and -5)
with a preference for Trp-Glu-His-Asp; group II (cas-
pases-2, -3 and -7) with a preference for Asp-Glu-X-Asp;
and group III (caspases-6, -8, -9 and -10) with a preference
for (Leu/Val)-Glu-X-Asp. 
A number of neurological diseases are connected to the
caspase apoptotic pathway [14–16] and some small caspase
inhibitors have been shown to block the effects of neu-
ronal cell death [17–20]. Given their pivotal role in the reg-
ulation of apoptosis, the caspases are important therapeutic
targets and it is clear that further investigation of caspase
specificity and its relationship to structure are important
for understanding cell death. We have determined the
structure of the active form of the protease of caspase-8 in
complex with the inhibitor benzyloxycarbonyl-Glu-Val-
Asp-dichloromethylketone (hereafter Z-EVD-dcbmk) in
order to further our understanding of the substrate speci-
ficity and with the aim of designing inhibitors of apoptosis. 
Results
The caspase-8 structure
During activation, procaspase-8 is proteolytically processed
to a heterodimeric entity consisting of one p18 and one p12
subunit (Figure 1). Each p18–p12 unit comprises six
β strands, five parallel (a,b,c,d,e) and one antiparallel (f),
that form a twisted β-sheet structure with two α helices
(H2,H3) on one side and three α helices (H1,H4,H5) on
the other running approximately parallel to the β strands.
The inhibitor extends along the active-site cavity that is
located at the C-terminal end of the parallel β strands
within each p18–p12 unit (Figure 1). Two p18–p12 units
associate, related by a twofold noncrystallographic symme-
try (NCS) axis, to form a (p18–p12)2 dimer that has a rec-
tangular structure of overall dimensions ~50 × 60 × 30 Å3
(Figure 1). There are six p18–p12 units (three independent
dimers) in the crystallographic asymmetric unit, a feature
that was used for both the structure determination (see
Materials and methods section) and to account for the
effects of packing interactions on the structure. The overall
topology of caspase-8 is similar to that of the previously
determined structures of caspase-1 [21,22] and caspase-3
[23,24]. Superposition of the caspase-8 structure with both
caspase-3 and caspase-1, based on the 140 Cα atom pairs
encompassing the core (six β strands and five α helices) of
one p18–p12 unit, gave root mean square deviations
(rmsds) of 0.8 Å and 0.9 Å, respectively. This observation
provides evidence for a high structural conservation within
these regions of the caspase family members. Despite this
similar architecture, striking differences do prevail in the
three loops (loops 1, 2 and 3) in the vicinity of the active
site (Figure 2). A prominent feature of caspase-8 is the sub-
stantially larger loop 1, having a seven and ten amino acid
insertion as compared to caspase-3 and caspase-1, respec-
tively. A short section of loop 1 of caspase-8 adopts an 
α-helical structure (residues 173–175d; see note in Figure 2
legend regarding nomenclature), which is absent from the
other two caspase structures. Loop 1 of caspase-8 runs
alongside the inhibitor and not only interacts with the P1
residue but also, uniquely to caspase-8, directly with the P3
residue of the inhibitor. Loop 2 of caspase-8 is not involved
in interactions with the inhibitor P1–P4 residues. This loop
is of comparable size and structure to that in caspase-3 and
substantially shorter than in caspase-1 (Figure 2). In con-
trast, the caspase-8 loop 3 is of intermediate size and has a
conformation that is dissimilar to those of the other caspase
structures. Loop 3 forms one side of the S4 pocket and
therefore directly affects the specificity at the P4 position
of the inhibitor. These features provide the basis for the
differences in substrate specificity and consequently for
the different functional role of the various caspases within
the apoptotic cascade.
The active site and inhibitor binding: the S1 and S2 pockets
In our complex of caspase-8 with the inhibitor, the
Z-EVD is shown clearly in the electron density to be
1126 Structure 1999, Vol 7 No 9
Figure 1
Ribbon diagram of the (p18–p12)2 dimer structure. The p18 and p12
chains are coloured red and green, respectively. The loops around the
active site are coloured dark blue and labelled. The inhibitor (Z-EVD),
which is covalently bound to the active-site cysteine Cys285, is
depicted as a yellow ball-and-stick model. The twofold NCS axis relating
the two p18–p12 units is perpendicular to the plane of the paper. (The
figure was generated using the program MOLSCRIPT [40].)
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covalently bound to the active-site cysteine (Cys285)
(Figure 3). The inhibitor lies in a surface cleft (Figure 4a)
and forms an antiparallel β-sheet interaction incorporating
the mainchain atoms of residues Ser339 and Arg341,
which follow β strand (e). The inhibitor further interacts
with amino acid sidechains from both the p18 and p12
chains (Figures 4b,c). The P1 aspartic acid sidechain pro-
jects into a well-defined cavity interacting with positively
charged amino acids lining the S1 pocket (Figures 4a,c).
In contrast, the S2 pocket is hydrophobic and the P2
valine lies in a region comprising Tyr340 and Val338, and
is capped by Tyr290 (Figure 4b). Comparing our struc-
ture of caspase-8 with caspase-3 and caspase-1 shows that
the nature of the environment around P1 and P2 is highly
conserved (Table 1). With the exception of the replace-
ment of a serine by Thr347 in caspase-8, the residues that
define the S1 pocket are identical to those in caspase-3
and caspase-1, which explains the near absolute speci-
ficity for a P1 aspartic acid residue within the entire
caspase family. The hydrophobic environment of the S2
pocket of the three caspases is also maintained as there
are only conservative amino acid substitutions (Table 1).
Kinetic studies using different peptide inhibitors have
led to the general consensus that the P2 amino acid is not
influential in the discrimination of substrate specificity
within the caspase family, but instead the P4 residue is
the dominant factor [25]. It is apparent from comparison
of these three caspases, however, that there are some
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Figure 2
Comparisons of the loop regions in different
caspases. (a) Cα representation of the loops
1, 2 and 3 of caspase-1 (blue), caspase-3
(red) and caspase-8 (green) after a Cα
superposition of the three caspases. The
inhibitor (Z-EVD) of caspase-8 is shown as a
magenta ball-and-stick model. The loops
around the inhibitor are labelled. (The figure
was generated using the program SETOR
[41].) (b) Amino acid sequence alignment of
the three caspases showing the loop regions
(residues in red). In caspase-8, loop 3 is five
residues shorter than in caspase-3 but four
residues longer than in caspase-1. The
position of the conserved caspase sequence
Gln-Ala-Cys-X-Gly, which encompasses the
active-site cysteine, is highlighted with a red
box. The positions of the p18 and p12 chain
are indicated below. (Note: The amino acid
numbering scheme adopted for the caspase-8
structure facilitates comparison with
caspase-1 (PDB entry 1ICE). Residues in
caspase-8 are assigned the numbers of the
homologous residues in the aligned three-
dimensional structure of caspase-1. The
caspase-8 sequence numbers are omitted
when no caspase-1-related residue is present
in caspase-8, and caspase-8-specific
insertions are indicated by the addition of
letters to the caspase-1 sequence numbers.)
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Figure 3
Electron density in the region of the covalently
bound inhibitor. The NCS-averaged
3Fo– 2Fcαcalc electron-density map
contoured at a 1.0σ level. Phases were
calculated on the model before inclusion of
the inhibitor in the refinement. The active-site
cysteine and inhibitor are shown in ball-and-
stick representation.
structural differences around the P2 residue that could
lead to subtle substrate specificity differences. In
caspase-8 the cavity size above the P2 residue is reduced
by the presence of Tyr290 (Figure 4b) in contrast to
caspase-1 where a more open cavity allows the accommo-
dation of a larger P2 residue, for example a histidine [26].
Intriguingly, in caspase-3 the loop 3, which is five amino
acids longer than in caspase-8, projects into the area
above the P2 residue and thus reduces the cavity volume.
These observations would suggest that caspases-8 and -3
have less tolerance for larger residues in the S2 pocket.
The S3 and S4 pockets: the major influences on substrate
specificity
Within the caspase family, differences in substrate speci-
ficity are predominantly conferred by those parts of the
structure that form subsites S3 and S4. In caspase-8,
Tyr340 replaces tryptophan in the other two caspases
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The active-site region of caspase-8 and inhibitor–enzyme interactions.
(a) Molecular surface representation of the active-site region with the
surface coloured according to its electrostatic potential: positive and
negative regions are indicated by blue and red, respectively. The
inhibitor is depicted as a stick model and coloured according to atom
type; the sulphur atom of the active-site cysteine is shown in green.
(The figure was generated using the program GRASP [42].)
(b) Stereoview of the active-site region of caspase-8. The inhibitor is
coloured orange and the enzyme residues that are important in
inhibitor interactions and substrate specificity are coloured purple;
other residues are in green. (The figure was generated using the
program SETOR [41].) (c) Schematic drawing of caspase-8 and the
Z-EVD inhibitor with hydrogen-bond interactions depicted as dashed
lines. (d) Stereoview superimposition of the S3, S4 active-site region of
caspase-8 (green) and caspase-3 (red). Superposition is based on Cα
atoms of the conserved core region of these caspases. The inhibitors
of caspase-8 and caspase-3 are coloured orange and magenta,
respectively. Sidechains in purple correspond to those of caspase-8
that differ from caspase-3. Labels are associated with caspase-8
residues. (The figure was generated using the program SETOR [41].)
(Figures 4b,d; Table 1), and Pro343 nonconservatively
replaces a serine in caspase-3. This latter substitution is
significant because in caspase-3–inhibitor complexes this
serine Oγ atom engages in a hydrogen-bond interaction
with the carboxylate group of the P3 glutamic acid. This
interaction influences the caspase specificity and con-
tributes to the preference for a P3 glutamic acid. In
caspase-8 and caspase-1, the hydrophobic nature of Pro343
would be expected to allow a hydrophobic amino acid in
the P3 position. Indeed, recent kinetic data [25] show a tol-
erance for a valine residue at the P3 site especially in
caspase-1, but less so in caspase-8. Interestingly, in
caspase-8 different hydrogen-bond interactions in the
presence of a glutamic acid residue at this site can be
observed. The Z-EVD inhibitor P3 glutamic acid sidechain
participates in a hydrogen-bond interaction with Arg341,
which is a highly conserved residue in the caspase family
(Figures 4b,c; Table 2). In caspase-8 there is an additional,
unpredicted hydrogen-bond interaction (3.4 Å) between
the sidechains of the P3 glutamic acid residue and Arg177
located on loop 1 (Figures 4b,c). The equivalent residue in
caspase-3 is a threonine and it is apparent that there could
not be a direct interaction of the threonine sidechain with
a P3 residue. In the structure of caspase-3 inhibited by
acetyl-Asp-Glu-Val-Asp-cho (Ac-DEVD-cho) [24], there is
an indirect interaction of the loop 1 threonine via a water
molecule with the P3 glutamic acid sidechain. These struc-
tural features explain the stringent specificity of caspase-8
for a glutamic acid residue at the P3 site.
In caspase-8, the S4 pocket incorporates residues Asn342
and Trp348 (Figure 4b). Equivalent residues are present in
caspase-3 and have an important function, forming hydro-
gen-bond interactions with the sidechain carboxylate group
of the P4 aspartic acid residue (Figure 4d). Specifically, in
caspase-3 three hydrogen-bond interactions occur with the
P4 aspartic acid residue — to Asn208 (3.4 Å), Trp214 Nε1
(3.1 Å), and the backbone amide group of Phe250 (2.7 Å)
located on loop 3 (where residue numbers are from
caspase-3 coordinates lcp3 [23]). It would be expected that
comparable interactions could occur involving residues
Asn342 and Trp348 in a caspase-8–inhibitor complex with
a P4 aspartic acid residue. A crucial and unpredicted discov-
ery is that in caspase-8 there is a shift of the backbone of
loop 3 away from the inhibitor, such that it is impossible to
form a hydrogen-bond interaction equivalent to that
observed between the Phe250 amide of caspase-3 and the
P4 sidechain (Figure 4d). In addition, the loop 3 aspartic
acid 381b lies on one side of the S4 pocket of caspase-8 pro-
viding a negative charge that would be unfavourable for a
P4 aspartic acid. These factors explain why caspase-8 pref-
erentially accommodates small hydrophobic residues at the
P4 position, whereas caspase-3 shows a strong preference
for an aspartic acid residue. Interestingly, our structure of
caspase-8 reveals an unpredicted hydrogen-bond inter-
action between the Asp381b Oδ1 atom and the Tyr340 OH
(2.7 Å) and this interaction stabilises the shifted loop 3 in
caspase-8 (Figure 4d); this interaction does not occur in
caspases-3 or -1 where a tryptophan replaces the tyrosine. 
The quaternary structure and dimer interface
The superposition of one p18–p12 unit from each of the
caspase-8, caspase-3 and caspase-1 structures reveals that
the orientation of their second p18–p12 units differs
within these (p18–p12)2 dimers and, as a consequence,
there is a difference in the angular relationship of the two
active sites within the dimer. The largest difference in the
rigid-body angle is between the second p18–p12 units of
caspase-1 and caspase-3 (13º). The dimer structure of
caspase-8 shows a relative arrangement of its two p18–p12
units that lies somewhat between that of caspase-1 and
caspase-3, but is just 5.5º from that of caspase-3. Integral
to the (p18–p12)2 dimer interface is an antiparallel inter-
action involving one β strand (f) from each of the two
p18–p12 units (Figure 5). Caspase-8 exhibits two main-
chain hydrogen bonds — an interaction between the back-
bone amide of Thr390 and the carbonyl oxygen of Pro389
(3.3 Å) and the symmetry-related interaction — these
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Table 2
Caspase-8–inhibitor hydrogen-bond interactions.
Inhibitor atom Caspase-8 atom Distance (Å)
P1 Asp Oδ1 Arg179 Nε 2.8
Arg341 NH1 2.6
Asp Oδ2 Arg179 NH2 3.7
Gln283 Nε2 2.9
Asp N Ser339 O 3.0
P3 Glu Oδ1 Arg177 NH1 3.4
Glu Oδ2 Arg341 NH2 2.6
Glu O Arg341 N 2.5
Glu N Arg341 O 3.0
Table 1
The substrate-pocket residues of caspases-8, -3 and -1.
Caspase-8 Caspase-3* Caspase-1
S1 Arg179 Arg64 Arg179 A
Arg341 Arg207 Arg341 B
Gln283 Gln161 Gln283 A
Ser339 Ser205 Ser339 B
Thr347 Ser213 Ser347 B
S2 Tyr340 Trp206 Trp340 B
Tyr290 Leu168
Val338 Tyr204 Val338 B
S3–S4 Tyr340 Trp206 Trp340 B
Arg341 Arg207 Arg341 B
Pro343 Ser209 Pro343 B
Trp348 Trp214 Val348 B
Asn342 Asn208 His342 B
*Residue numbering from the coordinates 1CP3 [23].
being innermost to the twofold NCS axis. This is different
in caspase-3 and caspase-1 where there are four mainchain
hydrogen bonds at this interface, albeit with a β-bulge
induced perturbation in the case of caspase-1. Caspase-8 is
structurally more closely related to caspase-3 and the dif-
ference in the interaction scheme is a direct consequence
of the amide nitrogen of Pro389 being unable to form a
hydrogen bond. 
The twofold NCS symmetry axis relating the two
p18–p12 units passes directly through the centre of a
cavity located at the (p18–p12)2 dimer interface
(Figures 1,5). In caspase-8 the dimensions of this cavity
are ~15 Å (length) × 10 Å (width) × 11 Å (depth), which is
~3 Å wider than in the other two caspases, ~2 Å shorter
than in caspase-3, and  ~4 Å longer than in caspase-1.
Intriguingly, in spite of the generally high sequence
homology (> 30%) between caspase-8 and caspase-3 the
environment of the interior of the cavity is strikingly dif-
ferent. The amino acids that are located on the central 
β strand (f) and which have sidechains protruding inwards
to form part of the cavity lining are hydrophilic in
caspase-8 (Figure 5). This is in contrast to caspase-3, the
cavity of which has a hydrophobic base with hydrophilic
sides; in this aspect caspase-8 is similar to caspase-1.
Within the cavities of these caspases there are variations
in the sidechain interactions. Of interest is the amino acid
that immediately follows the active-site cysteine
(Cys285), because within the conserved sequence 
Gln-Ala-Cys285-X-Gly this residue is highly conserved as
arginine within the caspase family, but in caspase-8 it is a
glutamine (Gln286). Our prototype structure with this
nonconservative substitution shows that the sidechain of
Gln286 engages in hydrogen-bond interactions with
neighbouring residues (Figure 5). This glutamine residue
does not extend far inside the central cavity. This is
unlike the situation observed in caspase-3 where the argi-
nine protrudes inwards with the NH2 group stacking
between a tyrosine and a proline residue, and in caspase-1
where the arginine forms a salt bridge with a glutamic
acid located across the cavity. It is the combined effects
of these interface sidechain and mainchain interactions
that determine the overall orientation of one p18–p12
unit with relation to the second within the caspase dimer. 
Discussion
An important characteristic of caspases is their ability to
discriminate between both small peptidic inhibitors as
well as endogenous and viral inhibitors. Our structure of
caspase-8 provides the first example from the group III
substrate specificity class and therefore has enabled us to
undertake a structural comparison incorporating represen-
tatives from each class. The relative substrate specificities
of caspases-8, -3 and -1 are attributed to the structural and
amino acid composition differences in both the substrate-
binding pockets and the loop regions around the active
site. The structure of caspase-8 provides information
about both loop 3 and loop 1 beyond what could be pre-
dicted from a homology modelling analysis [27] and which
is necessary to accurately assess substrate interactions.
The major differences between the caspase-8, -3 and -1
structures lie in the S3 and S4 regions. Earlier comparisons
between the caspase-3 and caspase-1 structures [23,24]
revealed differences at the P4 site that account for the
preferential inhibition of caspase-1 and caspase-3 by
YVAD-cho and Ac-DEVD-cho, respectively [28]. It was
thought that the predominant discriminating influence on
caspase substrate specificity was the nature of the S4
pocket. Certainly this pocket has a significant influence,
however, we believe that it is not sufficient to consider it
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Figure 5
The caspase-8 (p18–p12)2 dimer interface
and central cavity region. The twofold NCS
symmetry axis runs directly into the page
between the β strands f (green) and f′
(magenta) of the symmetry-related p18–p12
unit. Hydrogen bonds are illustrated as dotted
lines. The bound inhibitor is depicted in
orange. Gln286 (residue X of the conserved
QACXG sequence) is shown together with
the hydrogen-bond interactions in which it is
engaged. (The figure was generated using the
program SETOR [41].)
as being the sole discriminator of the substrate specificity.
Rather, from our structural results and comparisons, the
importance of the environment around the P3 amino acid
also has to be considered for substrate specificity and ulti-
mately in the design of specific inhibitors. 
Biological implications
Programmed cell death (apoptosis) is an important
process in maintaining homeostasis in multicellular
organisms. A family of cysteine proteases (caspases) has
been found to have an important role in this process.
Several different caspases have been identified some of
which (e.g. caspases-8 and -10) are known to be recruited
to the death receptors where they are activated. Other
caspases (e.g. caspases-3, -6 and -7) are activated down-
stream in a cascade of proteolytic events that is not yet
fully understood. These caspases cleave a variety of cellu-
lar substrates which ultimately lead to cell destruction.
The caspases have been classified into three subclasses
according to their substrate specificity. The availability
of the structures of caspase-1 (subclass I), caspase-3
(subclass II), and caspase-8 (subclass III, described
here) allows a correlation of the substrate specificity
with the observed structural differences at the molecular
level. The main differences between the three prototype
structures are localised in the specificity pockets S3 and
S4 and predominantly originate from the different loop
sizes forming these parts of the active sites. Although the
major discriminator site is subsite 4, in which hydropho-
bic substrate residues are preferred, the structures also
show the impact of subsite 3 for which there is a strin-
gent preference for glutamic acid. This observation cor-
relates with kinetic data available for the different
caspases. The structure/activity relationship will help in
the design of specific inhibitors of caspases. Such
inhibitors might be used as a means to influence the
apoptotic process in cells where this process is deregu-
lated and thought to be a contributing factor in the devel-
opment of neurodegenerative diseases or cancer.
Materials and methods
Caspase-8 preparation
Protein was expressed in bacteria using a plasmid containing the
prodomain-truncated version of the human caspase-8 cDNA (residues
131–403; equivalent to residues 221–496, protein sequence acces-
sion code 1401352) [29,30] inserted into the Bam HI–Xho I sites of
the pET21b expression plasmid (Novagen, Madison, WI). In this con-
struct the C terminus of the protein is fused to a polyhistidine tag. A
culture of BL21 (DE3) cells containing this plasmid was grown at
37°C in induction media (20 g/l tryptone, 10 g/l yeast extract, 5 g/l
NaCl, 0.5 × M9 salts 0.4% glucose, 1 mM MgCl2, 0.1 mM CaCl2,
0.1 mg/ml ampicillin, pH 7.4) [31]. When the culture density reached
A600 = 1,  isopropyl-β-D-thiogalactopyranoside (IPTG; Sigma, St Louis,
MO) was added to a concentration of 1 mM and the culture shaken at
25°C for 4 h. The induced cells were harvested by centrifugation and
resuspended in cold binding buffer (20 mM Tris-HCl, 5 mM imidazole,
500 mM NaCl, pH 8.0) containing 0.1 mg/ml lysozyme and 0.1%
triton X-100. Cells were frozen on dry ice and stored at –80°C. After
thawing, the cells were sonicated to reduce sample viscosity and cen-
trifuged at 30,000 × g for 40 min at 4°C. The lysate was filtered
through a 0.8 µM syringe filter and loaded onto a 10 ml Ni2+-charged
HiTrap chelating column (Amersham-Pharmacia, Piscataway, NJ).
After extensively washing the column with binding buffer containing
60 mM imidazole, the caspase-8 protein was eluted from the column
in 5 ml fractions using a 60–1000 mM imidazole gradient. The peak
fractions containing enzyme were diluted in an equal volume of cold
ICE buffer (25 mM HEPES, 1 mM EDTA, 2 mM dithiothreitol [DTT],
0.1% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonic
acid [CHAPS], 10% sucrose, pH 7.5). The sample was dialysed
against 25 mM Tris-HCl, 20 mm NaCl for 3 h, loaded onto a 1 ml
HiTrap Q anion exchange column equilibrated with the same buffer.
After loading, the column was washed with ten volumes of buffer; the
protein was eluted using a linear 25–1000 mM NaCl gradient. The
sample was concentrated by ultrafiltration to a concentration near
3 mg/ml, reduced with 50 mM DTT for 30 min at room temperature
and treated with a twofold molar excess of the inhibitor. After > 99%
of the enzyme was inhibited the sample was further concentrated by
ultrafiltration. The concentrated sample was passed through a column
containing 1 ml T7 tag antibody–agarose (Novagen) to remove trace
amounts of partially processed enzyme. The sample was then buffer
exchanged into crystallisation buffer (25 mM HEPES, 50 mM NaCl,
1 mM EDTA, pH 7.5) using a PD10 column (Amersham-Pharmacia).
The resulting sample (8 mg/ml) was highly pure as determined by
SDS–PAGE and mass spectrometry analysis and its enzymatic activity
was > 99.9% inhibited. Enzymatic activity of caspase-8 was deter-
mined from the initial rate of Ac-DEVD-amino-methyl coumarin
(Ac-DEVD-amc) substrate hydrolysis in ICE buffer. AMC production
was detected by the increase in the sample fluorescence
(excitation = 360 nM; emission = 460 nM) over a period of 1 h at room
temperature using a Cytofluor II fluorescent plate reader (Perseptive
Biosystems, Framingham, MA). The final substrate concentration was
10 µM and the enzyme concentration was 5 nM. Protein concentration
was determined with BioRad Protein assay with bovine serum albumin
as standard.
Structure determination
Crystals of the caspase-8–Z-EVD complex were obtained by vapour
diffusion by mixing equal amounts of protein solution (2–4 mg/ml) with
a reservoir solution consisting of 300 mM ammonium phosphate, 27%
(w/v) isopropanol and 100 mM sodium phosphate (pH 6.3). At 4°C the
first crystals appeared after a few days and continued to grow up to a
maximum size of 800 × 800 × 20 µm3 within two weeks. Macroseeding
significantly improved the thickness of the plate-like crystals. Diffraction
data were collected at 100K at the SNBL beamline (European Syn-
chrotron Radiation Facility [ESRF], Grenoble, France) on a 30 cm Mar
image plate detector and processed with the program MARXDS [32].
Crystals diffracted to better than 3 Å resolution and belong to space
group C2. The unit-cell dimensions were a = 93.90 Å, b = 206.53 Å,
c = 102.05 Å, β = 102.3° with six p18–p12 units — three (p18–p12)2
dimers — in the asymmetric unit. Data statistics are given in Table 3.
The structure of caspase-8 was solved by the molecular replacement
technique using the program AmoRe [33]. Homology models consist-
ing of two p18–p12 units (one (p18–p12)2 dimer) were built based on
structurally conserved regions, as determined from inspection of the
structures of caspase-1 [22] and caspase-3 [23]. Models were con-
structed that had variations in the rigid-body angle relating the two
p18–p12 units. Molecular replacement trials using these models were
undertaken with Patterson functions calculated using structure-factor
amplitudes, and also with normalised structure-factor amplitudes (Es).
Peaks for each of the three dimers were found amongst the 50 highest
calculated cross-rotation function peaks (using F, 8–4 Å resolution)
with peak heights of 6.0σ, 5.6σ and 5.5σ; the next highest peak being
4.5σ. The translation functions calculated for search models rotated
according to these rotation function solutions gave a correlation coeffi-
cient of 11.7% and R factor of 57.3% as the most promising result.
The position of this first molecule was fixed and the translation function
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search recalculated for the remaining rotation function solutions. This
gave a translation solution for a second dimer with a correlation coeffi-
cient of 18.8% and R factor of 55.2%. The positions of these two
dimers were fixed and a clear solution (19σ peak height, next peak
14σ) for the translation of the third dimer was determined (correlation
coefficient of 27.4%, R factor 53%). The orientations of the three
dimers were optimised by rigid-body refinement (correlation coefficient
of 60.5%, R factor of 47.7%). After a further rigid-body refinement
using X-PLOR [34], where each p18–p12 unit was treated as a rigid-
body, the molecular replacement solutions were redetermined with this
adjusted model and gave a correlation coefficient was 62.2% and 
R factor of 45.6%. Electron-density maps that were calculated with
phase information from the initial polyalanine molecular replacement
search model revealed electron density for the inhibitor (Z-EVD)
located in each of the six active sites. The inhibitor is clearly covalently
bound to the active-site cysteine residue but with a range of occu-
pancy, indicating flexibility. Molecular dynamics simulated annealing
(X-PLOR [34]) at 3000K with the incorporation of strong NCS
restraints, and initially with data (F > 2σ) and resolution 8 to 2.8 Å
gave an R factor of 38% and R free (based on 10% of the data) of
44%. Model building (program O [35]) was based on NCS-averaged
electron-density maps (DM [36,37]), phase-combined (SIGMAA
[37,38]) 3Fo–2Fcαcalc maps, and ~10% simulated-annealing
omit maps, and was followed by further refinement cycles. Data were
corrected for anisotropic diffraction and at a later stage a bulk-solvent
correction was applied and model refinement continued using all data
with F > 0.0. An initial rigid-body refinement was undertaken in
which each p18–p12 unit was defined as a rigid-body in order to allow
the determination of the optimal relationship of these units within the
dimer structure. Due to the low ratio of data to parameters, the follow-
ing refinements were performed with the incorporation of tight NCS
restraints (stronger restraints for backbone atoms than for sidechain
atoms) applied to the dimer model. In the later stages of refinement we
have loosened the restraints applied to residues of the loop regions,
whilst maintaining tighter restraints for the core regions (six β strands,
5 α helices). Only once the model had been almost completely built
and the statistics were reasonable (R factor = 32.5%, R free = 36.0%)
was the inhibitor incorporated into the model and ordered water mol-
ecules located. The electron-density maps are of sufficient quality to
determine the positions of the inhibitor P1, P2 and P3 amino acid
residues in each of the six p18–p12 units. However, in each case the
BZO group (Z) at the C terminus of the inhibitor was not well defined
in the electron density and remained ill-defined at later stages of model
refinement, and consequently was refined with zero occupancy. Group
individual isotropic B-factor refinement was carried out with one B
factor per residue. The present model comprises residues 149–299 of
the p18 chain, residues 318–401 of the p12 chain, the Z-EVD
inhibitor and 146 ordered water molecules. The Ramachandran plot
shows that 76% of residues lie in the most favoured regions, with 2%
being outliers. The assessment of these results using PROCHECK
[39] shows that this distribution is in the range observed in compara-
ble well-refined structures. The R free is 30.2% and the R factor is
23.0% for all data to 2.8 Å with reasonable stereochemistry (Table 3). 
Accession numbers
The coordinates of the caspase-8–Z-EVD complex have been deposited
with the Protein Data Bank (PDB) with accession code is 1QDU. 
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